---
phase: 03-vignette-review
verified: 2026-02-07T17:15:00Z
status: passed
score: 12/12 must-haves verified
re_verification: false
---

# Phase 3: Vignette Review Verification Report

**Phase Goal:** All vignettes are clear, informative, and render without errors
**Verified:** 2026-02-07T17:15:00Z
**Status:** PASSED
**Re-verification:** No — initial verification

## Goal Achievement

### Observable Truths

| # | Truth | Status | Evidence |
|---|-------|--------|----------|
| 1 | Estimand vignette opens with a problem-based hook and teaser code snippet before theory | ✓ VERIFIED | Lines 12-18 in estimand_and_implementations.Rmd show hook ("which variance estimator should you use?") followed by 3-line teaser code before theory content |
| 2 | A "Which method should I use?" section maps Ye to PATE and Ge to CPATE with practical guidance | ✓ VERIFIED | Section exists at line 68 with clear mapping, decision guidance, and clinical-trial-table cross-reference |
| 3 | Primary analysis example uses trial02_cdisc dataset (CDISC ADaM format) | ✓ VERIFIED | Lines 99-114 use trial02_cdisc with CDISC variable names (TRTP, AVAL, SEX, RACE, AGE) |
| 4 | Comparison section retains trial01 with explicit note explaining why | ✓ VERIFIED | Line 153 contains explicit note explaining trial01 usage due to pre-computed SAS validation datasets |
| 5 | Magirr et al. reference updated from OSF preprint to Pharmaceutical Statistics 2025 published version | ✓ VERIFIED | Lines 66 and 298 reference Magirr et al. (2025) with DOI 10.1002/pst.70021, no OSF links found |
| 6 | No package version numbers in references section | ✓ VERIFIED | grep "version [0-9]" returns no matches in any vignette |
| 7 | ARD vignette opens with a motivation scenario explaining why you need ARD integration | ✓ VERIFIED | Lines 19-25 in ard-cards-integration.Rmd present CSR Table 14.2.1 scenario before solution |
| 8 | ARD vignette uses trial02_cdisc dataset instead of trial01 | ✓ VERIFIED | Lines 36-39 use trial02_cdisc, grep for "trial01" returns no matches in ARD vignette |
| 9 | ARD vignette has no "Future Enhancements" section | ✓ VERIFIED | grep -i "Future Enhancements" returns no matches in ARD vignette |
| 10 | Clinical-trial-table vignette ends with a summary takeaway and cross-references | ✓ VERIFIED | Summary section at line 367 with workflow recap and cross-references to both other vignettes (lines 382-383) |
| 11 | All three vignettes render without errors via devtools::build_vignettes() | ✓ VERIFIED | devtools::build_vignettes() completed successfully, all three HTML outputs created |
| 12 | All vignettes use consistent cross-reference syntax | ✓ VERIFIED | All use backtick vignette('name') syntax, 8 cross-references total forming complete navigation web |

**Score:** 12/12 truths verified

### Required Artifacts

| Artifact | Expected | Status | Details |
|----------|----------|--------|---------|
| `vignettes/estimand_and_implementations.Rmd` | Polished with hook, method guidance, updated references | ✓ VERIFIED | 306 lines, substantive content, contains "Which method should I use" section, problem-based opening, Magirr 2025 reference |
| `vignettes/ard-cards-integration.Rmd` | Polished with motivation, trial02_cdisc, no future section | ✓ VERIFIED | 261 lines, substantive content, motivation scenario at line 19, trial02_cdisc throughout, no future enhancements section |
| `vignettes/clinical-trial-table.Rmd` | Polished with summary takeaway | ✓ VERIFIED | 400 lines, substantive content, comprehensive Summary section at line 367 with Next steps cross-references |

### Key Link Verification

| From | To | Via | Status | Details |
|------|-----|-----|--------|---------|
| estimand_and_implementations.Rmd | clinical-trial-table.Rmd | cross-reference | ✓ WIRED | Line 83 and 282: vignette('clinical-trial-table') |
| estimand_and_implementations.Rmd | ard-cards-integration.Rmd | cross-reference | ✓ WIRED | Line 283: vignette('ard-cards-integration') |
| ard-cards-integration.Rmd | estimand_and_implementations.Rmd | cross-reference | ✓ WIRED | Line 25 and 246: vignette('estimand_and_implementations') |
| ard-cards-integration.Rmd | clinical-trial-table.Rmd | cross-reference | ✓ WIRED | Line 247: vignette('clinical-trial-table') |
| clinical-trial-table.Rmd | estimand_and_implementations.Rmd | cross-reference | ✓ WIRED | Line 382: vignette('estimand_and_implementations') |
| clinical-trial-table.Rmd | ard-cards-integration.Rmd | cross-reference | ✓ WIRED | Line 383: vignette('ard-cards-integration') |

**All cross-references form a complete bidirectional navigation web.**

### Requirements Coverage

From ROADMAP.md Phase 3 Success Criteria:

| Requirement | Status | Evidence |
|-------------|--------|----------|
| 1. ARD vignette clearly explains ARD format and tells a good story | ✓ SATISFIED | Motivation scenario (lines 19-25), clear schema documentation (lines 44-62), mapping table (lines 93-106), multiple use cases (lines 141-209) |
| 2. Clinical trial reporting vignette demonstrates complete, realistic workflow | ✓ SATISFIED | End-to-end workflow (lines 63-147), publication-ready tables with metadata (lines 128-158), complete reporting example (lines 323-365), summary recap (lines 367-383) |
| 3. All vignettes (estimand_and_implementations, ARD, clinical reporting) render without errors | ✓ SATISFIED | devtools::build_vignettes() completed successfully with outputs for all three vignettes |

### Anti-Patterns Found

**None detected.** All verification scans passed:

```bash
# No preprint references
grep -i "osf.io\|preprint" vignettes/*.Rmd
# No matches

# No package version numbers
grep "version [0-9]" vignettes/*.Rmd
# No matches

# No stale trial01 references in ARD vignette
grep "trial01" vignettes/ard-cards-integration.Rmd
# No matches

# No Future Enhancements section in ARD vignette
grep -i "Future Enhancements" vignettes/ard-cards-integration.Rmd
# No matches
```

### Human Verification Required

None. All must-haves verified programmatically through file inspection and build verification.

---

## Detailed Verification Results

### Plan 03-01 Must-Haves (6/6 verified)

**1. Estimand vignette opens with a problem-based hook and teaser code snippet before theory**
- ✓ VERIFIED
- Location: `vignettes/estimand_and_implementations.Rmd` lines 12-20
- Evidence: Opens with "The FDA recommends covariate-adjusted analyses for randomized clinical trials, but which variance estimator should you use?" followed by 3-line code teaser using trial02_cdisc
- Hook precedes theory content about ICH E9(R1) (line 22)

**2. A "Which method should I use?" section maps Ye to PATE and Ge to CPATE with practical guidance**
- ✓ VERIFIED
- Location: `vignettes/estimand_and_implementations.Rmd` lines 68-83
- Evidence: 
  - Clear mapping: "use method = 'Ye'" for PATE (unconditional estimand)
  - Ge et al. method targets CPATE (conditional estimand)
  - Practical decision guide: "If in doubt, use method = 'Ye'"
  - Notes that point estimates are identical, only SEs differ
  - Cross-references clinical-trial-table vignette (line 83)

**3. Primary analysis example uses trial02_cdisc dataset (CDISC ADaM format)**
- ✓ VERIFIED
- Location: `vignettes/estimand_and_implementations.Rmd` lines 87-114
- Evidence: Example uses trial02_cdisc with CDISC variable names (TRTP, AVAL, SEX, RACE, AGE)
- Formula: `glm(AVAL ~ TRTP + SEX + RACE + AGE, family = "binomial", data = dat)`

**4. Comparison section retains trial01 with explicit note explaining why**
- ✓ VERIFIED
- Location: `vignettes/estimand_and_implementations.Rmd` line 153
- Evidence: "**Note:** For these cross-validation comparisons, we use the `trial01` dataset (2-arm trial) because pre-computed results from SAS macros (`margins_trial01`, `ge_macro_trial01`) are available for this dataset. The methodology applies identically to `trial02_cdisc`."
- Comparison section properly uses trial01 (lines 161-278)

**5. Magirr et al. reference updated from OSF preprint to Pharmaceutical Statistics 2025 published version**
- ✓ VERIFIED
- Locations: Lines 66 (inline) and 298 (references section)
- Evidence: 
  - Inline: `[Magirr et al. (2025)](https://doi.org/10.1002/pst.70021)`
  - References: "Magirr D, Wang C, Przybylski A, Baillie M (2025). Estimating the Variance of Covariate-Adjusted Estimators of Average Treatment Effects in Clinical Trials With Binary Endpoints. *Pharmaceutical Statistics* 24(4): e70021. https://doi.org/10.1002/pst.70021"
- No OSF links found in any vignette

**6. No package version numbers in references section**
- ✓ VERIFIED
- Evidence: `grep "version [0-9]" vignettes/*.Rmd` returns no matches
- All package references cite project URLs/DOIs without version numbers

### Plan 03-02 Must-Haves (6/6 verified)

**7. ARD vignette opens with a motivation scenario explaining why you need ARD integration**
- ✓ VERIFIED
- Location: `vignettes/ard-cards-integration.Rmd` lines 17-25
- Evidence: 
  - Scenario: "You've completed your covariate-adjusted analysis using `get_marginal_effect()` and obtained marginal treatment effects. Now you need to create Table 14.2.1 for your Clinical Study Report."
  - Lists specific needs: baseline characteristics, treatment effects, combined ARD
  - Transitions to solution explanation naturally

**8. ARD vignette uses trial02_cdisc dataset instead of trial01**
- ✓ VERIFIED
- Location: `vignettes/ard-cards-integration.Rmd` lines 36-39 (and throughout)
- Evidence: Setup chunk uses trial02_cdisc with CDISC variables (TRTP, AVAL, SEX, RACE, AGE)
- All code chunks reference `dat` (trial02_cdisc) or explicit CDISC variable names
- `grep "trial01" vignettes/ard-cards-integration.Rmd` returns no matches

**9. ARD vignette has no "Future Enhancements" section**
- ✓ VERIFIED
- Evidence: `grep -i "Future Enhancements" vignettes/ard-cards-integration.Rmd` returns no matches
- Vignette ends with "Next Steps" (lines 244-247) and "References" (lines 249-254), no future section

**10. Clinical-trial-table vignette ends with a summary takeaway and cross-references**
- ✓ VERIFIED
- Location: `vignettes/clinical-trial-table.Rmd` lines 367-383
- Evidence:
  - Summary section (lines 367-378) recaps workflow: get_marginal_effect(), as_gt(), beeca_summary_table(), beeca_fit(), tidy(), summary(), plot()
  - Notes dataset (trial02_cdisc) and method (Ye et al. 2023 for PATE)
  - "Next steps" subsection (lines 380-383) with cross-references to both estimand_and_implementations and ard-cards-integration vignettes

**11. All three vignettes render without errors via devtools::build_vignettes()**
- ✓ VERIFIED
- Evidence: Build output shows successful completion:
  - `Output created: ard-cards-integration.html`
  - `Output created: clinical-trial-table.html`
  - `Output created: estimand_and_implementations.html`
  - All three moved to doc/ successfully
  - No errors reported, only deprecated pandoc warnings (not related to vignette content)

**12. All vignettes use consistent cross-reference syntax**
- ✓ VERIFIED
- Evidence: All 8 cross-references use backtick vignette('name') syntax:
  - estimand_and_implementations.Rmd: `vignette('clinical-trial-table')` (2x), `vignette('ard-cards-integration')` (1x)
  - ard-cards-integration.Rmd: `vignette('estimand_and_implementations')` (2x), `vignette('clinical-trial-table')` (1x)
  - clinical-trial-table.Rmd: `vignette('estimand_and_implementations')` (1x), `vignette('ard-cards-integration')` (1x)
- No inconsistent formats found (no markdown links, no direct paths)

---

## Summary

All 12 must-haves from plans 03-01 and 03-02 are VERIFIED in the actual codebase:

**Plan 03-01 (estimand vignette):**
1. ✓ Problem-based hook and teaser code before theory
2. ✓ "Which method should I use?" section with Ye→PATE, Ge→CPATE mapping
3. ✓ Primary example uses trial02_cdisc
4. ✓ Comparison section retains trial01 with explanatory note
5. ✓ Magirr et al. updated to Pharmaceutical Statistics 2025
6. ✓ No package version numbers in references

**Plan 03-02 (ARD and clinical-trial-table vignettes):**
7. ✓ ARD vignette opens with CSR Table 14.2.1 motivation scenario
8. ✓ ARD vignette uses trial02_cdisc throughout (no trial01 references)
9. ✓ ARD vignette has no "Future Enhancements" section
10. ✓ Clinical-trial-table vignette ends with summary and cross-references
11. ✓ All three vignettes render without errors
12. ✓ Consistent cross-reference syntax across all vignettes

**ROADMAP.md Success Criteria:**
1. ✓ ARD vignette clearly explains ARD format and tells a good story
2. ✓ Clinical trial reporting vignette demonstrates complete, realistic workflow
3. ✓ All vignettes render without errors

**Phase Goal:** All vignettes are clear, informative, and render without errors — ACHIEVED

---

_Verified: 2026-02-07T17:15:00Z_
_Verifier: Claude (gsd-verifier)_
